- Investing Ideas
- /
- German Pharmaceuticals & Biotech Potentially Undervalued Companies
German Pharmaceuticals & Biotech Potentially Undervalued Companies
UPDATED Jul 02, 2022
Companies with a Value score of at least 3, ordered by Value score
471 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
| FUPFuji Pharma | JPÂ¥6.70 | 1.5% | -22.1% | JPÂ¥22.9b | JPÂ¥10.76 | PE10.2x | E16.6% | 3.3% | ||
| LDZAAspen Pharmacare Holdings | R8.00 | -1.8% | -15.8% | R62.7b | R14.10 | PE10.7x | E20.4% | 1.9% | ||
| LDZUAspen Pharmacare Holdings | R7.70 | -3.1% | -15.4% | R62.7b | R13.58 | PE10.7x | E20.4% | 1.9% | ||
| UQ1uniQure | US$18.69 | 3.3% | -27.5% | US$894.7m | US$51.59 | PE2.8x | E22.6% | n/a | ||
| ER4Emergent BioSolutions | US$29.25 | -4.8% | -45.7% | US$1.6b | US$40.89 | PE10.2x | E23.5% | n/a | ||
| B8FBiofrontera | €1.17 | 0% | -58.4% | €65.2m | €3.39 | PE4.3x | E30.9% | n/a | ||
| 354Collegium Pharmaceutical | US$16.80 | 3.1% | -16.0% | US$617.0m | US$26.70 | PE14.4x | E33.1% | n/a | ||
| 5HBShanghai Haohai Biological Technology | HK$4.94 | 6.0% | -53.0% | HK$17.9b | HK$8.24 | PE19.6x | E20.6% | 2.0% | ||
| PMRAPharma Mar | €66.62 | 4.3% | -13.9% | €1.2b | €78.19 | PE13.6x | E23.9% | 0.9% | ||
| R2WABeximco Pharmaceuticals | ৳0.80 | 4.6% | -15.8% | ৳69.0b | n/a | PE12x | E12.3% | 2.3% | ||
| UNJUnited Laboratories International Holdings | HK$0.55 | -0.9% | -14.2% | HK$8.4b | n/a | PE7.3x | E7.4% | 4.0% | ||
| C1SChina Shineway Pharmaceutical Group | HK$0.80 | 3.2% | -8.0% | HK$5.1b | n/a | PE7.8x | E10.3% | 6.8% | ||
| HPRHorizon Therapeutics | US$75.92 | -2.8% | -5.1% | US$18.6b | US$130.20 | PE21.6x | E24.3% | n/a | ||
| GEKAGenomma Lab Internacional. de | Mex$0.94 | -2.6% | 10.5% | Mex$20.4b | Mex$1.23 | PE13.9x | E17.9% | 1.9% | ||
| RV7Halozyme Therapeutics | US$41.81 | -6.1% | 7.3% | US$6.1b | US$51.70 | PE14.1x | E17.8% | n/a | ||
| RIG2Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt | Ft17.30 | 0.5% | -23.5% | Ft1.3t | Ft21.63 | PE8.6x | E19.0% | 3.2% | ||
| 2PQOrganogenesis Holdings | US$4.74 | 1.6% | -66.2% | US$645.7m | US$13.73 | PE7.6x | E8.5% | n/a | ||
| EX9Exelixis | US$20.52 | 12.7% | 34.2% | US$6.9b | US$25.27 | PE23.2x | E27.0% | n/a | ||
| LJPPLa Jolla Pharmaceutical | US$2.98 | -5.3% | -16.0% | US$79.7m | US$3.82 | PE15.2x | E42.2% | n/a | ||
| C1PConsun Pharmaceutical Group | HK$0.49 | 2.1% | -11.3% | HK$3.3b | HK$1.05 | PE4.7x | E10.3% | 6.8% | ||
| B8FEBiofrontera | €2.12 | 24.7% | -60.0% | €65.2m | €6.18 | PE4.3x | E30.9% | n/a | ||
| UQ1uniQure | US$17.80 | 3.4% | -30.3% | US$894.7m | US$49.14 | PE2.8x | E22.6% | n/a | ||
| ICYIncyte | US$72.08 | 1.6% | 1.8% | US$17.2b | US$85.67 | PE18.4x | E27.7% | n/a | ||
| PHECipher Pharmaceuticals | CA$1.58 | -1.1% | 50.7% | CA$55.9m | CA$2.52 | PE5.1x | E7.9% | n/a |